Results 131 to 140 of about 6,245 (175)

[Pituitary adenylate cyclase-activating polypeptide].

Annales d'endocrinologie, 1999
Pituitary adenylate cyclase-activating polypeptide (PACAP) has been originally isolated from the sheep hypothalamus on the basis of its ability to stimulate cAMP formation in anterior pituitary cells. Post-translational processing of the PACAP precursor generates two biologically active molecular forms, PACAP38 and PACAP27, and a novel peptide called ...
B J, Gonzalez, M, Basille, D, Vaudry, A, Fournier, H, Vaudry   +4 more
openaire   +1 more source

Pituitary adenylate cyclase activating polypeptide (PACAP)-like immunoreactivity in pheochromocytomas

Peptides, 1993
Pituitary adenylate cyclase activating polypeptide (PACAP) is a novel hypothalamic peptide consisting of 38 amino acids [PACAP(1-38)] with a potent stimulatory action on adenylate cyclase in rat pituitary. The presence of immunoreactive (IR-) PACAP in the tumor tissue of pheochromocytomas was studied by radioimmunoassay and immunocytochemistry.
K, Takahashi, K, Totsune, O, Murakami, M, Sone, K, Itoi, Y, Miura, T, Mouri   +6 more
openaire   +2 more sources

Neuronal protection from apoptosis by pituitary adenylate cyclase-activating polypeptide

Regulatory Peptides, 1997
Pituitary adenylate cyclase-activating polypeptide (PACAP) is known to have trophic effects on neurons. Apoptosis of PC12 cells was induced by depletion of serum and nerve growth factor (NGF) from culture medium. Not only high potassium-induced Ca2+ channel activation but PACAP-38 at physiological concentrations (10[-10] to 10[-8] M) protected PC12 ...
J, Tanaka, K, Koshimura, Y, Murakami, M, Sohmiya, N, Yanaihara, Y, Kato   +5 more
openaire   +2 more sources

Pituitary Adenylate-Cyclase-Activating Polypeptide Expression in the Immune System

Neuroimmunomodulation, 2002
Although pituitary adenylate-cyclase-activating polypeptide (PACAP) is a multifunctional and pleiotropic neuropeptide with many different immunomodulatory properties, investigations of its source in lymphoid organs are scarce. The present report contributes to the knowledge on the origin and synthesis of this peptide in immune cells of the lymphoid ...
Catalina, Abad, Carmen, Martinez, Javier, Leceta, Maria G, Juarranz, Mario, Delgado, Rosa P, Gomariz   +5 more
openaire   +2 more sources

Pituitary Adenylate Cyclase-Activating Polypeptide Prevents Cisplatin-Induced Renal Failure

Journal of Molecular Neuroscience, 2010
Cisplatin is widely used for cancer chemotherapy, but nephrotoxicity is a major dose-limiting side effect. Our recent studies in vitro have shown that pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorated cisplatin nephrotoxicity and that the renoprotection with PACAP38 was mediated by the PAC(1) receptor and through the p53-dependent ...
Min, Li, Saravanan, Balamuthusamy, Altaf M, Khan, Jerome L, Maderdrut, Eric E, Simon, Vecihi, Batuman   +5 more
openaire   +2 more sources

Pituitary adenylate cyclase activating polypeptide stimulates release of peptide YY

American Journal of Physiology-Endocrinology and Metabolism, 1993
The purpose of these experiments was to examine the effects of the recently discovered gastrointestinal peptide, pituitary adenylate cyclase activating polypeptide (PACAP), and two structurally related peptides, vasoactive intestinal polypeptide and secretin, on release of peptide YY (PYY) in conscious dogs.
T, Zhang, G, Gomez, N, Yanaihara, T, Mochizuki, J C, Thompson, G H, Greeley   +5 more
openaire   +2 more sources

Transcriptome of pituitary adenylate cyclase-activating polypeptide-differentiated PC12 cells

Regulatory Peptides, 2004
Addition of pituitary adenylate cyclase-activating polypeptide (PACAP) into the cultured PC12 cells secreted dopamine and promoted neurite outgrowth of the cells, indicating cell differentiation. To characterize the PACAP-differentiated PC12 cell transcriptome, we applied DNA macroarray techniques, using Atlas Rat 1.2 Array membranes (BD Biosciences ...
Masami, Ishido, Yoshinori, Masuo
openaire   +2 more sources

Pituitary adenylate cyclase‐activating polypeptide, effects in the human nose

Clinical & Experimental Allergy, 2003
SummaryBackground  Pituitary adenylate cyclase‐activating peptide (PACAP) is a neuropeptide with strong vaso‐ and bronchodilator capacity. There is recent evidence that PACAP decreases the release of proinflammatory cytokines and we have previously shown that PACAP inhibits neutrophil chemotaxis in vitro, but little is known about the effects of PACAP ...
J, Kinhult, M, Adner, R, Uddman, L O, Cardell   +3 more
openaire   +2 more sources

Cardiovascular and respiratory actions of pituitary adenylate cyclase-activating polypeptides

Regulatory Peptides, 1992
Effects of pituitary adenylate cyclase-activating polypeptide (PACAP38) and PACAP27 on the cardiovascular and respiratory systems were examined and compared to those of vasoactive intestinal polypeptide (VIP) in anesthetized beagle dogs. Intravenous PACAP27 and PACAP38 produced a decrease in mean arterial blood pressure (MBP), and an increase in both ...
Y, Ishizuka, K, Kashimoto, T, Mochizuki, K, Sato, K, Ohshima, N, Yanaihara   +5 more
openaire   +2 more sources

Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity

Neurobiology of Aging, 2014
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neurotrophin. However, its role in human Alzheimer's disease (AD) is largely unknown. We examined PACAP expression in postmortem human AD and triple transgenic mouse (3xTG, Psen1/APPSwe/TauP301L) brains.
Pengcheng, Han, Zhiwei, Tang, Junxiang, Yin, Marwan, Maalouf, Thomas G, Beach, Eric M, Reiman, Jiong, Shi   +6 more
openaire   +2 more sources